Reverse stock split intended to bring company into compliance with minimum bid price requirement for maintaining listing on Nasdaq Capital Market

Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerated

Trovagene receives "may proceed" notification from FDA for Phase 1b/2 trial of Onvansertib in combination with standard-of-care in patients with mCRC harboring KRAS mutations

Broad patent covers anti-androgen or androgen antagonist drugs, including combination treatment with Zytiga®, Xtandi® and Erleada® in multibillion-dollar market

- Preliminary Anti-Leukemic Activity Demonstrates >80% Response to Treatment with Onvansertib in Combination with Low-Dose Cytarabine (LDAC) or Decitabine in Dose Escalation Phase 1b of Trial

New website offers visitors greater insight into the Company's focus in oncology drug development, predictive clinical biomarkers and advances in Onvansertib clinical program

Targeted treatment with highly-selective, oral Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with standard-of-care chemotherapy may represent a new treatment option in AML

New patent claims strengthen patent estate revenue Aligns with Onvansertib Clinical Development and Biomarker Strategy in AML

-Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT

Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer types, expanding indications for Onvansertib

Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine in dose-escalation phase of trial

Company overview, update on Onvansertib clinical development program and anticipated near-term value-creation milestones

Target engagement and inhibition of PLK1 by Onvansertib predictive of treatment response

Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial

Onvansertib's product profile and attributes may offer the potential to provide significant clinical benefit with regard to efficacy and safety in patients with various types of cancer

Additional pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b/2 trial in Acute Myeloid Leukemia (AML)